Paul Conley
Managing Director @ Paladin Capital Group
Palo Alto, United States
Paul Conley is a Series A investor at Paladin Capital Group in Palo Alto focused on Biotechnology and Health Care. Dr. Conley leads new investments for the firm while serving as an active Director on many of Paladin’s portfolio company Boards. Paul joined the Paladin team after more than 15 years of previous R&D and entrepreneurial experience. As founding CEO of BrightScale, he led the commercialization of a patented multi-core microprocessor technology inthe HDTV market. As founding CEO of Appfluent Technology, he led the commercialization of patented in-memory distributed database technologies in the enterprise IT market. Prior to taking the entrepreneurial route, he spent nearly a decade in multidisciplinary R&D roles in the areas of high-performance computing, applied physics and biomedical engineering, including postdoctoral positions at the Los Alamos National Laboratory.
- Total investments:
- 24
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Paul Conley invests in
Stages Paul Conley invests in
Countries Paul Conley invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 10 (42%)
- Health Care 7 (29%)
- Life Science 5 (21%)
- Semiconductor 3 (13%)
- Medical 2 (8%)
Stage
- Series A 7 (29%)
- Series C 6 (25%)
- Series B 4 (17%)
- Series D 3 (13%)
- Seed 2 (8%)
Country
- United States 12 (50%)
- United Kingdom 2 (8%)
- Canada 1 (4%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Aralez Bio
|
Aralez Bio uses engineered enzymes to make valuable products in a sustainable way.The company has invented a novel enzymatic method for synthesizing noncanonical amino acids (ncAAs) also called unusual or unnatural amino acids. Its proprietary approach enables over 100 ncAAs to be synthesized with perfect enantiopurity in just a single step, withwater as the only byproduct | $12M / Series A / Oct 29, 2024 | |
Constructive Bio
|
Constructive is a ground-breaking method for creating wholly artificial genomes and rewriting the genetic code of living things. | $57.7M / Series A / Sep 24, 2024 | |
Alida Biosciences
|
Alida Biosciences is a biotech company creating RNA analysis tools to improve human health. The company was founded in 2020 and is headquartered in San Diego, CA. | $7.5M / Series A / Jun 12, 2024 | |
Infinimmune
|
Infinimmune operates as a biotechnology company. Infinimmune reinvents antibody discovery with an end-to-end platform to deliver antibody drugs derived directly from the human immune system. | $12M / Seed / Dec 06, 2022 | |
|
Alida Biosciences
|
Alida Biosciences is a biotech company creating RNA analysis tools to improve human health. The company was founded in 2020 and is headquartered in San Diego, CA. | $4M / Seed / May 11, 2022 | |
Menlo Micro
|
Menlo Micro is the developer of the Ideal Switch, an electromechanical switch technology used to switch AC/DC and RF. The Ideal Switch can handle high temperatures and high-stress conditions and help in battery management, home automation, and instrumentation that enable clients to work with advanced products and deliver efficient outcomesusing high power.Menlo Micro was founded in 2016 and is headquartered in Irvine, California. | $150M / Series C / Mar 09, 2022 | |
ONI
|
ONI is a pioneer of super-resolution microscopy, making this advanced technology accessible to new generations of researchers. The Nanoimager, the world's first benchtop sized super-resolution microscope, delivers a step change in usability and precision. This, together with our next-generation consumable products will empower academicresearchers, clinicians and scientists to on a path to discovery.The microscope offers easy access to a range of super-resolution techniques including dSTORM and PALM, as well as smFRET, single-particle tracking and confocal.The company's achievements have been recognised by FastTrack100 who named ONI on their 2018 list of 10 Disruptors to Watch and ONI won Best Business Start-up at the 2018 IOP Awards. More and more life science researchers and pharma companies are taking an interest in ONI and it now has customers using its products in leading laboratories across the globe, including the Universities of Oxford, Cambridge and Harvard.ONI has a restless enthusiasm to make the world a better place. Our ambition is to bring super-resolution fluorescence imaging to a new community of researchers and we are removing barriers to make science more effective, accessible and affordable. Our vision is to accelerate scientific discovery and fight disease by enabling everyone to visualize, understand and share the microscopic details of life. | $75M / Series B / Dec 24, 2021 | |
NanoCellect Biomedical
|
NanoCellect Biomedical, Inc. aims to make flow cytometry and cell sorting technology more affordable and accessible for life science researchers to perform cellular analysis, develop molecular diagnostics, and improve personalized medicine.A critical element for biomedical research is the ability for scientists to analyze and isolate cellsusing flow cytometers. Scientists use flow cytometers to obtain a fast, objective and quantitative recording of fluorescent signals from individual cells as well as physical separation of cells of particular interest.NanoCellect's mission is to facilitate breakthrough biomedical discoveries by making cell analysis and sorting technology more portable, affordable, and easier to use. We use microfluidics to make flow cytometers that enable biomedical scientists to analyze and sort cells required for drug discovery, diagnostics, or basic research. | $20M / Series D / Aug 13, 2021 | |
|
Alida Biosciences
|
Alida Biosciences is a biotech company creating RNA analysis tools to improve human health. The company was founded in 2020 and is headquartered in San Diego, CA. | $510K / Pre-Seed / Jul 02, 2021 | |
Edifice Health
|
Edifice Health is a spin-out company from a 10-year research study on immune profiling from Stanford University, the Stanford 1,000 Immunomes Project. The technology is the first biomarker composite scoring system to measure immune health and the Inflammatory Age® of an individual which predicts the onset of multiple chronic diseases and providescomprehensive health insights designed to help people change the course of their aging process. | $12M / Series A / Apr 22, 2021 | |
| See all 24 investments → | |||
Co-Investors
About Paladin Capital Group
Paladin Capital Group is a leading global investor that supports and grows the world’s most innovative companies through venture investment, expansion, and growth capital. Paladin is a leader in investing in technologies, products, and services focused on dual use in both commercial and governmental markets with a strong value-add culture. ThePaladin team merges financial expertise with national security and technical competence to add value across a wide array of market sectors and company stages. Paladin is focused on being an active investor—bringing decades of experience, advice, access, and relationships to its portfolio companies.Their most recent fund focuses on digital infrastructure resilience, investing globally in advanced technologies and solutions which enable, monitor, manage, and defend critical infrastructure that is dependent on cyber space. The firm is headquartered in Washington, DC, with offices in New York City, Silicon Valley, London, and Luxembourg.
Paladin Capital Group Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Chris Inglis
Managing Director
|
|||
Christopher Steed
Chief Investment Officer and Managing Director
|
|||
Kenneth Minihan
Managing Director
|
|||
Kenneth Pentimonti
Principal and European Manager
|
|||
Mark A. Maloney
Founder & Managing Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Paul Conley invest in?
Paul Conley invests primarily in Biotechnology, Health Care and Life Science startups, most often at Series A and Series C stage. Most of the 24 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Paul Conley?
Public channels for Paul Conley include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Paul Conley last invest?
The most recent investment recorded for Paul Conley closed in Oct 2024. Shizune tracks 24 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
